Your browser doesn't support javascript.
loading
Long-term Outcomes following Resection of Adenocarcinoma Arising from Intraductal Papillary Mucinous Neoplasm (A-IPMN) versus Pancreatic Ductal Adenocarcinoma (PDAC): A Propensity-score Matched Analysis.
Lucocq, James; Halle-Smith, James; Haugk, Beate; Joseph, Nejo; Hawkyard, Jake; Lye, Jonathan; Parkinson, Daniel; White, Steve; Mownah, Omar; Zen, Yoh; Menon, Krishna; Furukawa, Takaki; Inoue, Yosuke; Hirose, Yuki; Sasahira, Naoki; Mittal, Anubhav; Samra, Jas; Sheen, Amy; Feretis, Michael; Balakrishnan, Anita; Ceresa, Carlo; Davidson, Brian; Pande, Rupaly; Dasari, Bobby V M; Tanno, Lulu; Karavias, Dimitrios; Helliwell, Jack; Young, Alistair; Marks, Kate; Nunes, Quentin; Urbonas, Tomas; Silva, Michael; Gordon-Weeks, Alex; Barrie, Jenifer; Gomez, Dhanny; van Laarhoven, Stijn; Nawara, Hossam; Doyle, Joseph; Bhogal, Ricky; Harrison, Ewen; Roalso, Marcus; Ciprani, Debora; Aroori, Somaiah; Ratnayake, Bathiya; Koea, Jonathan; Capurso, Gabriele; Bellotti, Ruben; Stättner, Stefan; Alsaoudi, Tareq; Bhardwaj, Neil.
Afiliação
  • Lucocq J; Department of General Surgery, NHS Lothian, UK.
  • Halle-Smith J; Hepatobiliary and Pancreatic Surgery Unit, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, UK.
  • Haugk B; Hepatopancreatobiliary and Transplant Unit, Freeman Hospital, Newcastle upon Tyne, UK.
  • Joseph N; Hepatopancreatobiliary and Transplant Unit, Freeman Hospital, Newcastle upon Tyne, UK.
  • Hawkyard J; Hepatopancreatobiliary and Transplant Unit, Freeman Hospital, Newcastle upon Tyne, UK.
  • Lye J; Hepatopancreatobiliary and Transplant Unit, Freeman Hospital, Newcastle upon Tyne, UK.
  • Parkinson D; Hepatopancreatobiliary and Transplant Unit, Freeman Hospital, Newcastle upon Tyne, UK.
  • White S; Hepatopancreatobiliary and Transplant Unit, Freeman Hospital, Newcastle upon Tyne, UK.
  • Mownah O; Department of Hepatobiliary & Pancreatic Surgery, King's College Hospital, Denmark Hill, London, UK.
  • Zen Y; Department of Hepatobiliary & Pancreatic Surgery, King's College Hospital, Denmark Hill, London, UK.
  • Menon K; Department of Hepatobiliary & Pancreatic Surgery, King's College Hospital, Denmark Hill, London, UK.
  • Furukawa T; Cancer Institute Hospital of Japanese Foundation for Cancer Research, Hepato-Biliary-Pancreatic Medicine Department, Tokyo, Japan.
  • Inoue Y; Cancer Institute Hospital of Japanese Foundation for Cancer Research, Hepato-Biliary-Pancreatic Medicine Department, Tokyo, Japan.
  • Hirose Y; Cancer Institute Hospital of Japanese Foundation for Cancer Research, Hepato-Biliary-Pancreatic Medicine Department, Tokyo, Japan.
  • Sasahira N; Cancer Institute Hospital of Japanese Foundation for Cancer Research, Hepato-Biliary-Pancreatic Medicine Department, Tokyo, Japan.
  • Mittal A; Royal North Shore Hospital, Sydney, NSW, Australia.
  • Samra J; Royal North Shore Hospital, Sydney, NSW, Australia.
  • Sheen A; New South Wales Health Pathology, Dept of Anatomical Pathology, Royal North Shore Hospital, Sydney, NSW, Australia.
  • Feretis M; Cambridge Hepatobiliary and Pancreatic Surgery Unit, Addenbrooke's Hospital, Cambridge, UK.
  • Balakrishnan A; Cambridge Hepatobiliary and Pancreatic Surgery Unit, Addenbrooke's Hospital, Cambridge, UK.
  • Ceresa C; HPB and Liver Transplant Surgery, Royal Free London NHS Foundation Trust.
  • Davidson B; HPB and Liver Transplant Surgery, Royal Free London NHS Foundation Trust.
  • Pande R; Hepatobiliary and Pancreatic Surgery Unit, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, UK.
  • Dasari BVM; Hepatobiliary and Pancreatic Surgery Unit, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, UK.
  • Tanno L; Hepatobiliary and Pancreatic Surgery Unit, University Hospital Southampton, Southampton, UK.
  • Karavias D; Hepatobiliary and Pancreatic Surgery Unit, University Hospital Southampton, Southampton, UK.
  • Helliwell J; Hepatobiliary and Pancreatic Surgery Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Young A; Hepatobiliary and Pancreatic Surgery Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Marks K; Hepatobiliary and Pancreatic Surgery Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Nunes Q; Department of Hepatopancreatobiliary Surgery, East Lancashire Teaching Hospitals NHS Trust, UK.
  • Urbonas T; Oxford Hepato-Pancreato-Biliary (HPB) surgical unit, Oxford University Hospitals NHS Foundation Trust, UK.
  • Silva M; Oxford Hepato-Pancreato-Biliary (HPB) surgical unit, Oxford University Hospitals NHS Foundation Trust, UK.
  • Gordon-Weeks A; Oxford Hepato-Pancreato-Biliary (HPB) surgical unit, Oxford University Hospitals NHS Foundation Trust, UK.
  • Barrie J; Nottingham Hepato-Pancreatico-Biliary (HPB) Service, Nottingham University Hospitals NHS Foundation Trust, UK.
  • Gomez D; Nottingham Hepato-Pancreatico-Biliary (HPB) Service, Nottingham University Hospitals NHS Foundation Trust, UK.
  • van Laarhoven S; Department of Hepatobiliary and Pancreatic Surgery, University Hospitals Bristol & Weston NHS Foundation trust, UK.
  • Nawara H; Department of Hepatobiliary and Pancreatic Surgery, University Hospitals Bristol & Weston NHS Foundation trust, UK.
  • Doyle J; Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Bhogal R; Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Harrison E; Department of Clinical Surgery, University of Edinburgh, UK.
  • Roalso M; Department of Gastrointestinal Surgery, Stavanger University Hospital, Norway.
  • Ciprani D; Hepatopancreatobiliary Unit, University Hospitals Plymouth NHS Trust, Plymouth, UK.
  • Aroori S; Hepatopancreatobiliary Unit, University Hospitals Plymouth NHS Trust, Plymouth, UK.
  • Ratnayake B; Hepato-pancreatico-biliary/Upper Gastrointestinal Unit, North Shore Hospital, Auckland, NZ.
  • Koea J; Hepato-pancreatico-biliary/Upper Gastrointestinal Unit, North Shore Hospital, Auckland, NZ.
  • Capurso G; Pancreatico-Biliary Endoscopy and Endosonography Division, Pancreas Translational and Clinical Research Centre, San Raffaele Scientific Institute IRCCS, Vita-Salute San Raffaele University, Milan, Italy.
  • Bellotti R; Department of Visceral, Transplant and Thoracic Surgery, Centre of Operative Medicine, Medical University of Innsbrusk, 6020 Innsbruck, Austria.
  • Stättner S; Department of Visceral, Transplant and Thoracic Surgery, Centre of Operative Medicine, Medical University of Innsbrusk, 6020 Innsbruck, Austria.
  • Alsaoudi T; Leicester Hepatopancreatobiliary Unit, University Hospitals of Leicester NHS Trust, UK.
  • Bhardwaj N; Leicester Hepatopancreatobiliary Unit, University Hospitals of Leicester NHS Trust, UK.
Ann Surg ; 2024 Mar 22.
Article em En | MEDLINE | ID: mdl-38516777
ABSTRACT

OBJECTIVE:

The aim of the present study was to compare long-term post-resection oncological outcomes between A-IPMN and PDAC. SUMMARY BACKGROUND DATA Knowledge of long term oncological outcomes (e.g recurrence and survival data) comparing between adenocarcinoma arising from intraductal papillary mucinous neoplasms (A-IPMN) and pancreatic ductal adenocarcinoma (PDAC) is scarce.

METHODS:

Patients undergoing pancreatic resection (2010-2020) for A-IPMN were identified retrospectively from 18 academic pancreatic centres and compared with PDAC patients from the same time-period. Propensity-score matching (PSM) was performed and survival and recurrence were compared between A-IPMN and PDAC.

RESULTS:

459 A-IPMN patients (median age,70; MF,250209) were compared with 476 PDAC patients (median age,69; MF,262214). A-IPMN patients had lower T-stage, lymphovascular invasion (51.4%vs. 75.6%), perineural invasion (55.8%vs. 71.2%), lymph node positivity (47.3vs. 72.3%) and R1 resection (38.6%vs. 56.3%) compared to PDAC(P<0.001). The median survival and time-to-recurrence for A-IPMN versus PDAC were 39.0 versus19.5months (P<0.001) and 33.1 versus 14.8months (P<0.001), respectively (median follow-up,78 vs.73 months). Ten-year overall survival for A-IPMN was 34.6%(27/78) and PDAC was 9%(6/67). A-IPMN had higher rates of peritoneal (23.0 vs. 9.1%, P<0.001) and lung recurrence (27.8% vs. 15.6%, P<0.001) but lower rates of locoregional recurrence (39.7% vs. 57.8%; P<0.001). Matched analysis demonstrated inferior overall survival (P=0.005), inferior disease-free survival (P=0.003) and higher locoregional recurrence (P<0.001) in PDAC compared to A-IPMN but no significant difference in systemic recurrence rates (P=0.695).

CONCLUSIONS:

PDACs have inferior survival and higher recurrence rates compared to A-IPMN in matched cohorts. Locoregional recurrence is higher in PDAC but systemic recurrence rates are comparable and constituted by their own distinctive site-specific recurrence patterns.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article